STAAR Surgical reported net sales of $42.6 million for the first quarter of 2025, a 45% decrease year-over-year, primarily due to a planned reduction of channel inventory in China. The company incurred a net loss of $(54.2) million and an adjusted EBITDA loss of $(26.4) million. Despite the challenges in China, sales excluding China increased by 9% year-over-year.
Net sales decreased by 45% year-over-year to $42.6 million, driven by a planned reduction of channel inventory in China.
Sales excluding China increased by 9% year-over-year, reflecting growth in all key markets outside of China.
The company reported a net loss of $(54.2) million and an adjusted EBITDA loss of $(26.4) million.
Gross margin declined to 65.8% from 78.9% in the prior year, primarily due to intentional reduction in U.S. production volumes and higher manufacturing costs.
STAAR Surgical has withdrawn its previously provided financial outlook due to global economic uncertainty and evolving tariff policy, but remains confident in its efforts to mitigate tariff exposure and its long-term business trends.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance